International Stem Cell (ISCO) Cash from Financing Activities (2010 - 2022)
International Stem Cell (ISCO) posted quarterly Cash from Financing Activities of $250000.0 for Q1 2022, down 69.66% year-over-year from $824000.0 in Q1 2021, and down 69.66% quarter-over-quarter from $824000.0 in Q1 2021.
International Stem Cell (ISCO) Cash from Financing Activities (2010 - 2022) Analysis & Trends
International Stem Cell (ISCO) has reported Cash from Financing Activities for 12 consecutive years, with $250000.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Cash from Financing Activities fell 69.66% year-over-year to $250000.0; the TTM figure through Dec 2022 stood at $250000.0 (down 69.66% YoY), while the FY2025 annual figure was -$200000.0, changed 0.0% from the prior year.
- Cash from Financing Activities slipped to $250000.0 in Q1 2022 per ISCO's latest filing, from $824000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $1.4 million in Q3 2018 and bottomed at -$53000.0 in Q1 2019.
- Historically, Cash from Financing Activities has averaged $543111.1 across 4 years, with a median of $500000.0 in 2019.
- On a YoY basis, Cash from Financing Activities climbed as much as 4066.67% in 2019 and fell as far as 113.52% in 2019.
- International Stem Cell's Cash from Financing Activities stood at $12000.0 in 2018, then jumped by 4066.67% to $500000.0 in 2019, then jumped by 64.8% to $824000.0 in 2021, then plunged by 69.66% to $250000.0 in 2022.
- Business Quant data shows ISCO's Cash from Financing Activities at $250000.0 in Q1 2022, $824000.0 in Q1 2021, and $500000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 250,000.00 |
| Mar 31, 2022 | 250,000.00 |
| Mar 31, 2021 | 824,000.00 |
| Mar 31, 2021 | 824,000.00 |
| Dec 31, 2019 | 500,000.00 |
| Dec 31, 2019 | 500,000.00 |
| Jun 30, 2019 | 853,000.00 |
| Jun 30, 2019 | 853,000.00 |
| Mar 31, 2019 | -53,000.00 |
| Mar 31, 2019 | -53,000.00 |
| Dec 31, 2018 | 12,000.00 |
| Dec 31, 2018 | 12,000.00 |
| Sep 30, 2018 | 1.38 Mn |
| Sep 30, 2018 | 1.38 Mn |
| Jun 30, 2018 | 735,000.00 |
| Jun 30, 2018 | 735,000.00 |
| Mar 31, 2018 | 392,000.00 |
| Mar 31, 2018 | 392,000.00 |
| Dec 31, 2017 | 500,000.00 |
| Dec 31, 2017 | 500,000.00 |